(Q57667480)

English

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

scientific article published on 08 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

osteogenesis imperfecta

0 references

1 reference

based on heuristic

inferred from title

Robert Graham G Russell

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Matthew A. Brown

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

L A Bradbury

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

S Barlow

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

F Geoghegan

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R A Hannon

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

S L Stuckey

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J A H Wass

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

8 July 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Osteoporosis International

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

285-294

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

https://scigraph.springernature.com/pub.10.1007/s00198-011-1658-2

0 references

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Intravenous bisphosphonate therapy in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Intravenous neridronate in adults with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Effects of zoledronic acid in adults with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Impact of alendronate on quality of life in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Effect of alendronate therapy in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Bone turnover markers in patients with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1658-2

21 January 2018

Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteogenesis imperfecta after the menopause

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonate therapy for osteogenesis imperfecta

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21739105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-011-1658-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21739105%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57667480&oldid=2090527647"